Search Result

Results for "

DAT inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Dopamine Transporter (33) 5-HT Receptor (14) Adenylate Cyclase (3) Adrenergic Receptor (9) Apoptosis (5) Biochemical Assay Reagents (1) CDK (1) Dopamine Receptor (8) Drug Metabolite (3) Histamine Receptor (5) Histone Methyltransferase (2) iGluR (1) Isotope-Labeled Compounds (5) mAChR (5) Microtubule/Tubulin (1) Monoamine Transporter (6) Potassium Channel (4) Reference Standards (8) Serotonin Transporter (20) Sigma Receptor (1) Sodium Channel (6) Trk Receptor (5)
By Research Areas:	Cancer (4) Endocrinology (4) Inflammation/Immunology (5) Neurological Disease (59)

By Targets:

Dopamine Transporter (33)

5-HT Receptor (14)

Adenylate Cyclase (3)

Adrenergic Receptor (9)

Apoptosis (5)

Biochemical Assay Reagents (1)

CDK (1)

Dopamine Receptor (8)

Drug Metabolite (3)

Histamine Receptor (5)

Histone Methyltransferase (2)

iGluR (1)

Isotope-Labeled Compounds (5)

mAChR (5)

Microtubule/Tubulin (1)

Monoamine Transporter (6)

Potassium Channel (4)

Reference Standards (8)

Serotonin Transporter (20)

Sigma Receptor (1)

Sodium Channel (6)

Trk Receptor (5)

By Research Areas:

Cancer (4)

Endocrinology (4)

Inflammation/Immunology (5)

Neurological Disease (59)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Dopamine Transporter

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13217

Vanoxerine dihydrochloride 5+ Cited Publications GBR-12909 dihydrochloride; I893 dihydrochloride	Dopamine Transporter	Neurological Disease
Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) is a competitive, potent, and highly selective dopamine reuptake inhibitor (K_i=1 nM). Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) binds to the target site on the dopamine transporter (DAT) .

HY-B0527A

Amitriptyline hydrochloride 5+ Cited Publications	Serotonin Transporter 5-HT Receptor mAChR Histamine Receptor Adrenergic Receptor Trk Receptor Sodium Channel Potassium Channel Dopamine Transporter Apoptosis	Neurological Disease Inflammation/Immunology Endocrinology
Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (K_i = 3.45 nM) and NET (K_i = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to *DAT* (with K_i = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (K_i = 11-24 nM), H1 receptors (K_i = 0.5-1.1 nM), adrenergic α1 receptors (K_i = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC₅₀ = 4.78 μM) and it has cardiotoxicity .

HY-14258

Escitalopram 10+ Cited Publications (S)-Citalopram; (S)-(+)-Citalopram	Serotonin Transporter	Neurological Disease
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .

HY-B0527

Amitriptyline 5+ Cited Publications	Serotonin Transporter Trk Receptor Sodium Channel 5-HT Receptor Histamine Receptor Adrenergic Receptor mAChR Potassium Channel Dopamine Transporter Apoptosis	Neurological Disease Inflammation/Immunology Endocrinology
Amitriptyline is an orally active tricyclic antidepressant (TCA). Amitriptyline mainly exerts its antidepressant effect by blocking SERT (K_i = 3.45 nM) and NET (K_i = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline can reduce inflammation, angiogenesis and fibrosis. Amitriptyline binds to *DAT* (with K_i = 2.58 μM). Amitriptyline has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (K_i = 11-24 nM), H1 receptors (K_i = 0.5-1.1 nM), adrenergic α1 receptors (K_i = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline can block sodium channels and hERG potassium channel (IC₅₀ = 4.78 μM) and it has cardiotoxicity .

HY-14258A

Escitalopram oxalate Maximum Cited Publications 11 Publications Verification (S)-Citalopram oxalate; (S)-(+)-Citalopram oxalate	Serotonin Transporter	Neurological Disease Cancer
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-W016388

9-Fluorenol 9-Hydroxyfluorene	Dopamine Receptor Drug Metabolite	Neurological Disease
9-Fluorenol (9-Hydroxyfluorene; compound 3) is a dopamine (DAT) inhibitor with IC₅₀ value of 9 µM. 9-Fluorenol is a major metabolite of compound developed as a wake promoting agent. 9-Fluorenol shows wake promotion activity in vivo .

HY-Y1191

EEDQ EEDQ	Biochemical Assay Reagents 5-HT Receptor Dopamine Transporter	Neurological Disease
EEDQ is a carboxylate activator and irreversible antagonist of 5HT2c receptors. EEDQ reduces [ ³H]β-CIT binding to the dopamine transporter (DAT) in rat caudate-putamen (CPu) homogenates (IC₅₀ = 78.3 μM). EEDQ inhibits contralateral rotation behavior .

HY-19907

Liafensine BMS-820836	Dopamine Transporter Monoamine Transporter Serotonin Transporter	Neurological Disease
Liafensine (BMS-820836) is an orally active, blood-brain barrier-permeable monoamine reuptake inhibitor, with an IC₅₀ of 5.67 nM against *DAT, 1.08 nM against SERT, and 7.99 nM against NET. Liafensine binds to DAT* to block dopamine reuptake. Liafensine binds to SERT to block serotonin reuptake. Liafensine binds to NET to block norepinephrine reuptake. Liafensine can be used in studies related to depression .

HY-101315

AHN 1-055 hydrochloride 3 Publications Verification 3α-Bis-(4-fluorophenyl) Methoxytropane hydrochloride	Dopamine Transporter	Neurological Disease
AHN 1-055 hydrochloride is a dopamine uptake inhibitor that can cross the blood-brain barrier, with an IC₅₀ of 71 nM. AHN 1-055 hydrochloride binds with high affinity to the dopamine transporter (DAT) .

HY-103430A

SKF-83566 2 Publications Verification	Dopamine Receptor 5-HT Receptor Adenylate Cyclase	Neurological Disease
SKF-83566 is a potent, blood-brain permeable and orally active D1-like dopamine receptor (D1DR) antagonist and a weaker competitive antagonist at the vascular 5-HT₂ receptor (K_i=11 nM) . SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC₅₀ of 5.7 μM . SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC₁ and AC₅ in the isolated rabbit thoracic aorta . SKF-83566 can be used for research of parkinson’s disease and nicotine craving alleviation .

HY-161723

LH2-051	Dopamine Transporter CDK	Neurological Disease
LH2-051, a lysosome-enhancing compound (LYEC), is a brain-penetrant dopamine transporter (DAT) inhibitor (K_i: 0.95 μM). LH2-051 inhibits *DAT*-mediated dopamine uptake with an IC₅₀ of 3.0 μM. LH2-051 promotes nuclear translocation of TFEB and lysosome biogenesis. LH2-051 improves the memory of amyloid precursor protein (APP)/Presenilin 1 (PS1) mice. LH2-051 can be used for the study of Alzheimer’s disease .

HY-13217A

Vanoxerine 5+ Cited Publications GBR 12909; I893	Dopamine Transporter	Neurological Disease
Vanoxerine (GBR-12909) is a competitive, potent, and highly selective dopamine reuptake inhibitor (K_i=1 nM). Vanoxerine (GBR-12909) binds to the target site on the dopamine transporter (DAT) .

HY-133116

4-Hydroxyatomoxetine	Adrenergic Receptor	Neurological Disease
4-Hydroxyatomoxetine is an active metabolite of Atomoxetine. 4-Hydroxyatomoxetine is metabolized by the enzyme cytochrome P450 2D6 (CYP2D6). Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (K_i values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-158013A

JJC8-088 dioxalate	Dopamine Transporter	Neurological Disease
JJC8-088 dioxalate is the dioxalate salt form of JJC8-088 (HY-158013). JJC8-088 dioxalate is a derivative of modafinil. JJC8-088 dioxalate is an inhibitor for dopamine transporter (DAT). JJC8-088 dioxalate exhibits behavioral characteristics similar to cocaine in rat models, and can be to study psychostimulant use disorders .

HY-14258AR

Escitalopram oxalate (Standard) (S)-Citalopram oxalate (Standard); (S)-(+)-Citalopram oxalate (Standard)	Reference Standards Serotonin Transporter	Neurological Disease Cancer
Escitalopram (oxalate) (Standard) is the analytical standard of Escitalopram (oxalate). This product is intended for research and analytical applications. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-N7506

13-Hydroxyisobakuchiol Delta3,2-Hydroxylbakuchiol	Monoamine Transporter Dopamine Transporter	Neurological Disease
13-Hydroxyisobakuchiol (Delta3,2-Hydroxylbakuchiol), an analog of Bakuchiol (HY-N0235) that can be isolated from Psoralea corylifolia (L.), is a potent selective monoamine transporter inhibitor. 13-Hydroxyisobakuchiol is more selective for the dopamine transporter (DAT) (IC₅₀ = 0.58 μM) and norepinephrine transporter (NET) (IC₅₀ = 0.69 μM) than for the serotonin transporter (SERT) (IC₅₀ = 312.02 μM). 13-Hydroxyisobakuchiol increases the activity of intact mice and improves the decreased activity of reserpinized mice in vivo. 13-Hydroxyisobakuchiol can be used for the research of disorders such as Parkinson's disease and depression .

HY-B0527AR

Amitriptyline hydrochloride (Standard) 4 Publications Verification	Reference Standards Serotonin Transporter 5-HT Receptor Histamine Receptor mAChR Adrenergic Receptor Trk Receptor Sodium Channel Potassium Channel Dopamine Transporter Apoptosis	Neurological Disease Inflammation/Immunology Endocrinology
Amitriptyline hydrochloride (Standard) is the analytical standard of Amitriptyline hydrochloride (HY-B0527A). This product is intended for research and analytical applications. Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (K_i = 3.45 nM) and NET (K_i = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to *DAT* (with K_i = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (K_i = 11-24 nM), H1 receptors (K_i = 0.5-1.1 nM), adrenergic α1 receptors (K_i = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC₅₀ = 4.78 μM) and it has cardiotoxicity.

HY-17590

Radafaxine hydrochloride 1 Publications Verification (S,S)-Hydroxybupropion hydrochloride; GW-353162A; BW-306U	Monoamine Transporter	Neurological Disease
Radafaxine hydrochloride (GW-353162A) is a DAT (dopamine transporter) and NET(norepinephrine transporter) transporters inhibitor, and nAChR family modulator.

HY-163384

(S)-CE-123	Dopamine Transporter	Neurological Disease
(S)-CE-123 is a potent, selective, and novel atypical dopamine transporter (DAT) inhibitor with an EC₅₀ of 2.76 μM in uptake inhibition assays conducted in HEK293 cells stably expressing human isoforms of DAT. (S)-CE-123, a Modafinil analogue, is able to penetrate the blood–brain barrier. (S)-CE-123 improves cognitive and motivational processes in experimental animals .

HY-14840A

(R)-Phenylpiracetam MRZ 9547	Dopamine Transporter	Neurological Disease Inflammation/Immunology
(R)-Phenylpiracetam (MRZ 9547) is a dopamine transporter (DAT) inhibitor (K_i: 14.8 μM; IC₅₀: 65.5 μM). (R)-Phenylpiracetam can be used for the research of the neurological or neuropsychiatric disorders .

HY-135096

Amitriptyline-d3 hydrochloride	Serotonin Transporter 5-HT Receptor Histamine Receptor mAChR Adrenergic Receptor Sodium Channel Trk Receptor	Neurological Disease
Amitriptyline-d3 hydrochloride is the deuterium labeled Amitriptyline (hydrochloride). Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with K_is of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a K_i of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and 5-HT receptors. Amitriptyline hydrochloride is a TrkA and TrkB receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity .

HY-117902

SRI-31142	Dopamine Transporter	Neurological Disease
SRI-31142 is a putative, brain-penetrant allosteric inhibitor of the dopamine transporter (DAT). In behavioral studies using intracranial self-stimulation (ICSS), SRI-31142 did not produce the abuse-related effects seen with cocaine and GBR-12935, but instead reduced ICSS responses and dopamine levels in the nucleus accumbens (NAc) at effective doses. SRI-31142 also blocked cocaine-induced increases in ICSS and NAc dopamine .

HY-B0527AS

Amitriptyline-d6 hydrochloride	Isotope-Labeled Compounds Serotonin Transporter 5-HT Receptor Histamine Receptor mAChR Adrenergic Receptor Trk Receptor Sodium Channel Potassium Channel Dopamine Transporter Apoptosis	Neurological Disease Inflammation/Immunology Endocrinology
Amitriptyline-d₆ hydrochloride is the deuterium labeled Amitriptyline hydrochloride (HY-B0527A). Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (K_i = 3.45 nM) and NET (K_i = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to *DAT* (with K_i = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (K_i = 11-24 nM), H1 receptors (K_i = 0.5-1.1 nM), adrenergic α1 receptors (K_i = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC₅₀ = 4.78 μM) and it has cardiotoxicity.

HY-158013

JJC8-088	Dopamine Transporter	Neurological Disease
JJC8-088, a Modafinil-derived ligand, is a dopamine transporter (DAT) inhibitor with a K_i of 2.53 nM. JJC8-088 dioxalate can be to study psychostimulant use disorders .

HY-14258AS

Escitalopram-d6 oxalate	Serotonin Transporter	Neurological Disease
Escitalopram-d₆ (oxalate) is the deuterium labeled Escitalopram oxalate. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-107055

RTI 336	Dopamine Transporter	Neurological Disease
RTI 336 is a phenyltropane analog, as well as a potent and selective dopamine transporter (DAT) inhibitor. RTI 336 inhibits addictive agent induced locomotor activity and self-administration in Lewis rats. RTI 336 exhibits inhibitory effects depending on inherent NAc DAT levels .

HY-172421

Cendifensine	Monoamine Transporter Serotonin Transporter Dopamine Transporter	Neurological Disease
Cendifensine is the inhibitor for monoamine reuptake that inhibits the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT) .

HY-107128

Ampreloxetine hydrochloride TD-9855 hydrochloride	Serotonin Transporter	Neurological Disease
Ampreloxetine (TD-9855) hydrochloride is an orally active and CNS-penetrant inhibitor of Norepinephrine transporter (NET) and Serotonin 5-HT uptake transporter (SERT), but not Dopamine transporter (DAT). Ampreloxetine hydrochloride binds norepinephrine transporters (NET) and serotonin transporters (SERT) with EC₅₀ values of 11.7 ng/mL and 50.8 ng/mL, respectively, in plasma .

HY-158014

JJC8-089	Dopamine Transporter	Neurological Disease
JJC8-089 is a dopamine transporter (DAT) inhibitor that may improve motivational dysfunction and increase effortful behavior in goal-directed activities. JJC8-089 significantly reversed the low-effort effects induced by the VMAT-2 inhibitor Tetrabenazine (HY-B0590) in rats and increased the choice of high-effort fixed-ratio 5-bar presses versus food intake. .

HY-18332B

DOV-102,677	Dopamine Transporter Adrenergic Receptor 5-HT Receptor	Neurological Disease
DOV-102,677 is an orally sctive triple monoamine neurotransmitter reuptake inhibitor that simultaneously inhibits the dopamine (DAT) (IC₅₀ = 129 nM; K_i = 222 nM), norepinephrine (NET) (IC₅₀ = 103 nM; K_i = 1030 nM), and serotonin (SERT) (IC₅₀ = 133 nM; K_i = 740 nM) transporters. DOV-102,677 demonstrated significant antidepressant-like activity and sensory-motor gating regulatory effects in mouse experiments. DOV-102,677 can be used for research on depression .

HY-14258AS1

Escitalopram-d4 oxalate (S)-Citalopram-d4 oxalate; (S)-(+)-Citalopram-d4 oxalate	Isotope-Labeled Compounds Serotonin Transporter	Neurological Disease
Escitalopram-d₄ (oxalate) is deuterium labeled Escitalopram (oxalate). Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-178907

SERT/5-HT-IN-1	Serotonin Transporter 5-HT Receptor	Neurological Disease
SERT/5-HT-IN-1 (compound D17) is an orally active and potent dual target inhibitor of SERT/5-HT3A (SERT IC₅₀ = 1.5 nM, NET IC₅₀ = 49 nM, *DAT* IC₅₀ = 91 nM, 5-HT3A K_i = 12 nM). SERT/5-HT-IN-1 has an IC₅₀ of 39 nM to 5-HT3A. SERT/5-HT-IN-1 has a lower risk of liver, kidney, and cardiac toxicity. SERT/5-HT-IN-1 can be used for research on depressive disorders .

HY-163156

JJC12-009	Dopamine Transporter	Neurological Disease
JJC12-009 is a dopamine transporter (DAT) inhibitor, with a K_i of 5.45 nM .

HY-117473

DAT-230	Microtubule/Tubulin Apoptosis	Cancer
DAT-230 is a microtubule inhibitor. DAT-230 induces cell apoptosis and results in microtubule de-polymerization and G2/M phase arrest. DAT-230 inhibits cell growth in vitro and in vivo .

HY-163138

DAT-IN-1	Dopamine Transporter	Neurological Disease
DAT-IN-1 (Coumpound 12b) is an atypical *DAT* inhibitor with a K_i of 8.37 nM. DAT-IN-1 can be used in the study of psychostimulant use disorder (PSUD) .

HY-169807

O-2172	Dopamine Transporter	Others
O-2172, a carbacyclic analog, is a *DAT* inhibitor, with IC₅₀ values of 47 nM and 7000 nM for DAT and SERT, respectively .

HY-163155

RDS03-94	Dopamine Transporter	Neurological Disease
RDS03-94 is a dopamine transporter (DAT) inhibitor. RDS03-94 reduces hERG/DAT ratio .

HY-126158

SRI-29574	Dopamine Transporter Serotonin Transporter	Neurological Disease
SRI-29574 is an allosteric modulator of the dopamine transporter (DAT). SRI-29574 partially inhibits the uptake of the *DAT* (IC₅₀=2.3 nM) and also partially inhibits the uptake of the serotonin transporter (SERT) and norepinephrine transporter (NET). SRI-29574 may serve as a useful probe to study the function and regulatory mechanisms of DAT .

HY-163154

JJC8-091	Dopamine Transporter	Neurological Disease
JJC8-091 is a potent dopamine transporter (DAT) inhibitor with K_i values of 230, 97800 nM for DAT, SERT, respectively. JJC8-091 has the potential for the research of psychostimulant use disorders (PSUD) .

HY-161913

AC-4-248	Dopamine Transporter	Neurological Disease
AC-4-248 is an atypical non-competitive dopamine transporter (DAT) inhibitor and reduces the potency of cocaine to inhibit DAT. AC-4-248 is a non-selective inhibitor of SLC6 transporters with IC₅₀ values for hDAT, hSERT, and hNET of 45.5 μM, 96.2 μM, and 250 μM, respectively .

HY-117512

UWA-101 hydrochloride	Dopamine Transporter Serotonin Transporter	Neurological Disease
UWA-101 hydrochloride is a selective and non-cytotoxic *DAT/SERT* inhibitor, with EC₅₀ values of 3.6 µM and 2.3 µM for inhibiting *DAT* and SERT, respectively. UWA-101 hydrochloride can alleviate the side effects of dopaminergic agents (such as L-DOPA), such as motor disorders, and lacks psychotropic activity. UWA-101 hydrochloride can be used for research on neurodegenerative diseases such as Parkinson's disease .

HY-174282

RDS-04-010	Dopamine Transporter	Neurological Disease
RDS-04-010 is an atypical dopamine transporter (DAT) inhibitor. RDS-04-010 has the effect of inhibiting cocaine intake and seeking behavior. RDS-04-010 exerts its modulatory effect mainly by binding to the inward conformation of DAT, thereby reducing the reinforcing effect of cocaine. RDS-04-010 can be used in the study of cocaine use disorder (CUD) .

HY-173475

CM699	Sigma Receptor Dopamine Transporter	Neurological Disease
CM699 is a potent Dopamine Transporter (DAT) and Sigma-receptor (σR) dual inhibitor with IC₅₀s of 311 and 14.1 nM, respectively .

HY-172029

3,4-Methylenedioxy pyrovalerone metabolite 2 hydrochloride	Monoamine Transporter	Neurological Disease
3,4-Methylenedioxy pyrovalerone metabolite 2 hydrochloride is an analog of Pyrovalerone. Pyrovalerone inhibits the dopamine transporter (DAT)，serotonin transporter (SERT)，and the norepinephrine transporter (NET) .

HY-110223

Atomoxetine-d3 hydrochloride	Adrenergic Receptor	Neurological Disease
Atomoxetine-d3 hydrochloride is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (K_i values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-17385S

Atomoxetine-d5 hydrochloride Tomoxetine-d5 hydrochloride; LY 139603-d5 ; (R)-Tomoxetine-d5 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor	Neurological Disease
Atomoxetine-d₅ (hydrochloride) is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-107370AS

(Rac)-Atomoxetine-d7 hydrochloride (Rac)-Tomoxetine d₇ hydrochloride; (Rac)-LY 139603 d₇	Serotonin Transporter Sodium Channel Isotope-Labeled Compounds	Neurological Disease
(Rac)-Atomoxetine-d₇ (hydrochloride) is a deuterium labeled (Rac)-Atomoxetine hydrochloride. (Rac)-Atomoxetine hydrochloride is a racemic form of Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-13217R

Vanoxerine dihydrochloride (Standard) GBR-12909 dihydrochloride (Standard); I893 dihydrochloride (Standard)	Dopamine Transporter Reference Standards	Neurological Disease
Vanoxerine (dihydrochloride) (Standard) is the analytical standard of Vanoxerine (dihydrochloride). This product is intended for research and analytical applications. Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) is a competitive, potent, and highly selective dopamine reuptake inhibitor (Ki=1 nM). Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) binds to the target site on the dopamine transporter (DAT) .

HY-116062A

JNJ-7925476	Histone Methyltransferase	Neurological Disease
JNJ-7925476 is a triple reuptake inhibitor that selectively and potently inhibits the activity of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). JNJ-7925476 is rapidly absorbed into the blood and its concentration in the brain is 7-fold higher than that in plasma. The occupancy ED(50) values of JNJ-7925476 for SERT, NET, and DAT in the rat brain are 0.18, 0.09, and 2.4 mg/kg, respectively. JNJ-7925476 rapidly induces a significant increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex in a dose-dependent manner. JNJ-7925476 exhibits potent antidepressant-like activity in the mouse tail suspension test. These results suggest that JNJ-7925476 has in vivo efficacy in biochemical and behavioral models of depression .

HY-W016388R

9-Fluorenol (Standard) 9-Hydroxyfluorene (Standard)	Reference Standards Dopamine Receptor Drug Metabolite	Neurological Disease
9-Fluorenol (Standard) is the analytical standard of 9-Fluorenol. This product is intended for research and analytical applications. 9-Fluorenol (9-Hydroxyfluorene; compound 3) is a dopamine (DAT) inhibitor with IC50 value of 9 μM. 9-Fluorenol is a major metabolite of compound developed as a wake promoting agent. 9-Fluorenol shows wake promotion activity in vivo .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14258

Escitalopram 10+ Cited Publications (S)-Citalopram; (S)-(+)-Citalopram	Natural Products Endogenous metabolite Source Classification	Serotonin Transporter
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .

HY-N7506

13-Hydroxyisobakuchiol Delta3,2-Hydroxylbakuchiol	Structural Classification Monophenols Leguminosae Phenols Psoralea corylifolia L. Plants Source Classification	Monoamine Transporter Dopamine Transporter
13-Hydroxyisobakuchiol (Delta3,2-Hydroxylbakuchiol), an analog of Bakuchiol (HY-N0235) that can be isolated from Psoralea corylifolia (L.), is a potent selective monoamine transporter inhibitor. 13-Hydroxyisobakuchiol is more selective for the dopamine transporter (DAT) (IC₅₀ = 0.58 μM) and norepinephrine transporter (NET) (IC₅₀ = 0.69 μM) than for the serotonin transporter (SERT) (IC₅₀ = 312.02 μM). 13-Hydroxyisobakuchiol increases the activity of intact mice and improves the decreased activity of reserpinized mice in vivo. 13-Hydroxyisobakuchiol can be used for the research of disorders such as Parkinson's disease and depression .

HY-14258R

Escitalopram (Standard) (S)-Citalopram (Standard); (S)-(+)-Citalopram (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Serotonin Transporter Reference Standards
Escitalopram (Standard) is the analytical standard of Escitalopram. This product is intended for research and analytical applications. Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .

Cat. No.	Product Name	Chemical Structure

HY-B0527AS

Amitriptyline-d6 hydrochloride

Amitriptyline-d₆ hydrochloride is the deuterium labeled Amitriptyline hydrochloride (HY-B0527A). Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (K_i = 3.45 nM) and NET (K_i = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to DAT (with K_i = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (K_i = 11-24 nM), H1 receptors (K_i = 0.5-1.1 nM), adrenergic α1 receptors (K_i = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC₅₀ = 4.78 μM) and it has cardiotoxicity.

HY-14258AS

Escitalopram-d6 oxalate

Escitalopram-d₆ (oxalate) is the deuterium labeled Escitalopram oxalate. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-14258AS1

Escitalopram-d4 oxalate

Escitalopram-d₄ (oxalate) is deuterium labeled Escitalopram (oxalate). Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-17385S

Atomoxetine-d5 hydrochloride
Atomoxetine-d₅ (hydrochloride) is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-107370AS

(Rac)-Atomoxetine-d7 hydrochloride
(Rac)-Atomoxetine-d₇ (hydrochloride) is a deuterium labeled (Rac)-Atomoxetine hydrochloride. (Rac)-Atomoxetine hydrochloride is a racemic form of Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-W751669

9-Fluorenol-d9
9-Fluorenol-d₉ (9-Hydroxyfluorene-d₉) is the deuterium labeled 9-Fluorenol (HY-W016388). 9-Fluorenol (9-Hydroxyfluorene; compound 3) is a dopamine (DAT) inhibitor with IC₅₀ value of 9 μM. 9-Fluorenol is a major metabolite of compound developed as a wake promoting agent. 9-Fluorenol shows wake promotion activity in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks